What is CJC-1295 + Ipamorelin Blend and how does the dual-pathway mechanism work?

CJC-1295 + Ipamorelin Blend combines two synergistic growth hormone secretagogues: CJC-1295 (a GHRH analog activating GHRH receptors via Gs-coupled cAMP-PKA signaling) and Ipamorelin (a selective ghrelin receptor agonist activating GHS-R1a via Gq-coupled calcium mobilization). This dual-pathway approach produces supraadditive GH release by converging cAMP and calcium signaling on pituitary somatotroph secretory machinery. The synergistic mechanism involves: (1) CJC-1295 binding GHRH receptors triggering adenylyl cyclase activation, cAMP generation, and PKA-mediated CREB phosphorylation for GH gene transcription, (2) Ipamorelin binding ghrelin receptors causing phospholipase C activation, IP3 generation, and calcium release from intracellular stores, and (3) Convergent signaling where elevated cAMP-PKA and calcium simultaneously activate GH vesicle fusion and exocytosis, producing GH release 8-15x baseline (vs 4-6x for either alone). The blend formulation provides precise ratiometric dosing in single vial, simplifying dual-pathway research protocols while ensuring consistent synergistic GH stimulation for investigating maximal secretory capacity, pulsatile GH patterns, and multi-receptor signaling interactions.

What research applications benefit from the synergistic CJC-1295 + Ipamorelin combination?

The blend excels in synergistic GH secretion research investigating dual-pathway amplification mechanisms, maximal somatotroph secretory capacity studies, pulsatile GH pattern optimization, GH-IGF-1 axis dynamics with enhanced stimulation, cAMP-PKA and calcium signaling convergence mechanisms, GHRH and ghrelin receptor cross-talk investigations, age-related somatopause and GH restoration studies, metabolic research requiring robust GH elevation, muscle protein synthesis pathway activation, comparative single vs dual secretagogue studies, dose-response relationship mapping for combination protocols, and peptide synergy pharmacology. The pre-formulated blend eliminates mixing variability, ensures consistent CJC-1295:Ipamorelin ratio, and simplifies research protocols compared to separate peptide administration. Ideal for endocrinology labs investigating GH physiology, neuroendocrine research centers studying hypothalamic-pituitary regulation, metabolic research programs examining growth factor effects, and pharmaceutical development optimizing secretagogue combinations. The selective nature of Ipamorelin (minimal cortisol, prolactin, appetite effects) combined with CJC-1295's potent GHRH activity makes this blend the gold standard for clean GH release research without confounding off-target effects.

What purity and quality standards does your CJC-1295 + Ipamorelin Blend meet?

Our blend exceeds >98% combined purity with each component verified independently by HPLC analysis. Quality control includes: dual-peptide HPLC demonstrating separate peaks for CJC-1295 (29 amino acids) and Ipamorelin (pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2) with proper retention times and >98% purity for each, mass spectrometry molecular weight confirmation for both components (CJC-1295 ~3367 Da, Ipamorelin ~711 Da), peptide sequence verification confirming CJC-1295's four amino acid substitutions and Ipamorelin's selective D-amino acid modifications, ratiometric validation ensuring consistent CJC-1295:Ipamorelin proportions across batches, dual bioactivity testing measuring both cAMP accumulation (GHRH-R activation) and calcium mobilization (GHS-R1a activation), synergistic GH secretion assays from pituitary cells demonstrating 8-15x GH release exceeding either peptide alone, endotoxin screening ( 98% purity ensures reproducible synergistic GH release without interference from degradation products. All testing validates both chemical identity (correct sequences for both peptides, proper ratio) and biological activity (dual receptor activation, synergistic GH secretion) critical for reliable multi-pathway GH research.

How does the blend compare to administering CJC-1295 and Ipamorelin separately?

The pre-formulated blend offers significant advantages: (1) Consistent ratio - pharmaceutical-grade formulation ensures identical CJC-1295:Ipamorelin proportion in every dose, eliminating variability from separate mixing, (2) Simplified protocols - single reconstitution and administration reduces procedural complexity and potential for dosing errors, (3) Enhanced reproducibility - standardized formulation produces more consistent synergistic GH release across experiments compared to variable manual mixing, (4) Quality control - dual-peptide HPLC and mass spec verify both components simultaneously with ratiometric validation, (5) Cost efficiency - single product with combined CoA documentation vs purchasing and validating two separate peptides, and (6) Research convenience - ideal for high-throughput studies, core facilities, and large-scale projects requiring standardization. However, separate peptides allow independent dose titration for investigating dose-response relationships or non-standard ratios. Choose the blend for standardized synergistic GH research, consistent multi-pathway protocols, and simplified procedures. Choose separate peptides when investigating variable ratio effects, independent dose optimization, or mechanistic studies requiring selective pathway manipulation. Both approaches achieve dual-pathway synergy - the blend optimizes convenience, consistency, and reproducibility for routine research applications.

How should CJC-1295 + Ipamorelin Blend be stored and reconstituted?

Store lyophilized blend at -20°C in original sealed vials for 24+ months stability. Both CJC-1295 and Ipamorelin maintain chemical stability when co-lyophilized and frozen. Reconstitute by adding bacteriostatic water (0.9% benzyl alcohol) or sterile saline slowly down the vial wall, then gently swirl (never shake) until both peptides completely dissolve at typical concentration 1-5 mg/mL total peptide. Refrigerate reconstituted solution at 2-8°C and use within 14 days to maintain optimal dual bioactivity. Both components remain stable in solution when refrigerated together. Avoid multiple freeze-thaw cycles which can degrade peptide structures and alter the CJC-1295:Ipamorelin ratio. For studies requiring multiple dosing, aliquot reconstituted solution into single-use sterile vials immediately after reconstitution to prevent repeated temperature cycling. Store aliquots at 2-8°C. Proper storage ensures consistent dual GHRH-R and GHS-R1a activation, reproducible synergistic GH secretion, and reliable multi-pathway signaling research. The co-formulated blend maintains stability matching separate peptides when handled correctly - providing convenience without compromising quality for combination secretagogue research protocols.

What makes the CJC-1295 + Ipamorelin combination uniquely synergistic?

The synergy arises from complementary signaling pathway convergence: CJC-1295 activates Gs-coupled cAMP-PKA pathway while Ipamorelin activates Gq-coupled calcium pathway - these dual second messenger systems converge on GH secretory machinery producing supraadditive amplification. Mechanistically: cAMP-PKA phosphorylates proteins facilitating GH vesicle trafficking and priming, calcium triggers vesicle fusion and exocytosis, and simultaneous activation produces GH release exceeding the sum of individual effects (8-15x baseline vs 4-6x for CJC-1295 alone, 4-8x for Ipamorelin alone). Ipamorelin's selectivity for GHS-R1a (minimal off-target effects - no appetite stimulation like GHRP-6, no cortisol elevation like GHRP-2, no prolactin effects) makes it ideal for clean synergistic GH studies. CJC-1295's potent GHRH-R activation with enhanced DPP-4 resistance (~30 min half-life) provides sustained cAMP signaling. Together they represent optimal dual-pathway stimulation: maximal GH release with minimal confounding effects. This synergy cannot be replicated by increasing single-pathway stimulation - dual convergence is mechanistically distinct, making the combination valuable for investigating cross-talk between cAMP and calcium signaling, studying maximal somatotroph capacity, and understanding physiological GH regulation involving multiple secretagogue systems.

What dosage variants and bulk pricing are available for the blend?

We offer CP10 (10mg total peptide per 10-vial kit) specification. Pricing: $200/kit (1 kit), $190/kit (20+ kits receiving ~5% discount), $180/kit (50+ kits receiving ~10% discount). The 10mg concentration supports diverse research applications from pilot synergistic GH studies to extensive multi-week combination secretagogue protocols. The formulation contains both CJC-1295 and Ipamorelin in pharmaceutical-grade ratio optimized for maximal synergistic GH release based on published dual-pathway research. Bulk pricing reflects complex dual-peptide manufacturing requiring independent synthesis, ratio validation, and combined stability testing while maintaining >98% purity for both components. The blend is more cost-effective than purchasing equivalent amounts of CJC-1295 and Ipamorelin separately (savings of ~15-20% plus simplified procurement and documentation). For large-scale combination secretagogue research, multi-year GH physiology projects, institutional core facility procurement, or pharmaceutical development programs investigating synergistic peptide formulations, contact via WhatsApp to discuss custom quantity requirements and volume pricing. The standardized blend formulation ensures reproducible synergistic GH research for academic endocrinology labs, pharmaceutical companies developing secretagogue combinations, and research institutions investigating multi-pathway GH regulation worldwide.

How do you validate synergistic GH release in bioactivity assays?

Beyond chemical purity (dual HPLC, mass spec for both peptides), we perform comprehensive synergy bioassays: (1) GH secretion assays - treating primary rat/mouse pituitary cells or somatotroph cell lines with CJC-1295 alone (measuring cAMP-mediated GH release), Ipamorelin alone (measuring calcium-mediated GH release), and the blend (measuring synergistic GH release), quantifying GH via ELISA demonstrating 8-15x increase for blend vs 4-6x CJC-1295 alone, 4-8x Ipamorelin alone - confirming supraadditive amplification, (2) Dual receptor activation assays - simultaneously measuring cAMP accumulation (GHRH-R Gs activation) and calcium mobilization (GHS-R1a Gq activation) confirming both pathways engaged, (3) Dose-response characterization - testing multiple blend concentrations to establish EC50 and maximal response, (4) Time-course studies - measuring GH secretion kinetics showing rapid onset from dual-pathway convergence, (5) Pathway validation - using PKA inhibitors to block cAMP pathway and calcium chelators to block calcium pathway, demonstrating synergy requires both intact, and (6) Comparison to individual peptides - side-by-side testing proving blend produces identical synergy to separately administered peptides at equivalent doses. CoA includes synergistic GH secretion data (fold-increase, statistical analysis confirming supraadditivity) ensuring physiologically relevant dual-pathway bioactivity. These assays validate the blend's core value - synergistic GH amplification from cAMP-calcium convergence.

Can the blend be used in comparative studies with other secretagogue combinations?

Absolutely! Researchers frequently use CJC-1295 + Ipamorelin blend in comparative studies against: (1) CJC-1295 + GHRP-6 - comparing selective (Ipamorelin) vs appetite-stimulating (GHRP-6) ghrelin agonists for GH synergy while examining confounding metabolic effects, (2) CJC-1295 + GHRP-2 - investigating selectivity differences, cortisol elevation, and off-target effects, (3) CJC-1295 + Hexarelin - comparing standard synergistic GH release vs Hexarelin's additional cardioprotective effects and higher GH potency, (4) Sermorelin + Ipamorelin - comparing CJC-1295's enhanced stability vs Sermorelin's shorter half-life in combination protocols, (5) Single secretagogues alone - quantifying the added benefit of dual-pathway activation vs single-pathway maximal stimulation, and (6) Other dual-agonist approaches - comparing sequential dual-pathway stimulation vs co-administration synergy. The standardized blend formulation enables rigorous comparisons with controlled variables, while separate peptide administration allows exploring variable ratios and timing. Comparative research reveals: optimal secretagogue pairings for maximal GH release, trade-offs between GH potency and selectivity, importance of off-target effects in interpreting metabolic outcomes, and mechanistic differences between cAMP-calcium convergence patterns. These studies advance understanding of multi-pathway GH regulation and optimize combination secretagogue protocols for specific research endpoints.

What documentation supports CJC-1295 + Ipamorelin Blend research compliance?

Each batch includes comprehensive Certificate of Analysis: dual-peptide HPLC chromatogram showing separate peaks for CJC-1295 and Ipamorelin with retention times, purity quantification (>98% for each), and ratio validation, mass spectrometry data confirming molecular weights (CJC-1295 ~3367 Da with 29 amino acids, Ipamorelin ~711 Da with Aib-His-D-2-Nal-D-Phe-Lys-NH2 sequence), peptide sequence verification for both components including CJC-1295's four amino acid substitutions and Ipamorelin's D-amino acid modifications, synergistic GH secretion bioassay results demonstrating 8-15x GH release with statistical analysis confirming supraadditivity vs individual peptides, dual receptor activation data showing cAMP accumulation (GHRH-R) and calcium mobilization (GHS-R1a), endotoxin testing (<0.1 EU/mg), batch number and manufacturing date for traceability, ratiometric specifications confirming consistent CJC-1295:Ipamorelin proportion, storage recommendations, and suggested reconstitution protocols. This documentation satisfies institutional biosafety committees, research compliance audits, and regulatory requirements for dual-peptide formulation procurement. International worldwide shipping uses lyophilized formulation with cold pack insulation in sealed packaging. Delivery takes 10-14 days with tracking. Upon arrival, immediately transfer to -20°C storage. The comprehensive CoA ensures research-grade quality for synergistic GH studies, dual-pathway signaling research, and combination secretagogue investigations at academic and pharmaceutical laboratories worldwide.

Home ProductsCJC-1295 + Ipamorelin Blend

Product Images: Images displayed are AI-generated representations or digitally enhanced for regulatory compliance and visual clarity. Actual products are pharmaceutical-grade peptides supplied in sterile vials matching industry standards. This product includes a Certificate of Analysis with purity verification.

CJI10

CJC-1295 + Ipamorelin Blend

For research and laboratory use only. Not for human consumption.

Dual-secretagogue GH blend: CJC-1295 5mg + Ipamorelin 5mg for synergistic growth hormone research

Blend Composition

CJC-1295 (GHRH Analog)5mg

Ipamorelin (Ghrelin Agonist)5mg

Pick Your Size

Select Quantity

Researcher·1 Kit

Volume pricing

Per-kit price drops as you scale

Add 1 more kit

Unlock Lab pricing at $260/kit

+$190

extra savings

Total Price

$355

Free Worldwide Shipping

No minimum order. Customs handled.

Express Delivery

7-14 Days

Ships To

190+ Countries

Customs Handled

99% Success Rate

Stealth Packaging

Cold-Chain

Lab-Grade Guarantee

If an independent HPLC assay of your lot comes back below the purity stated on our published Certificate of Analysis, we reship your order free. Verifiable, not a promise.

99.24% Purity Verified

HPLC / ESI-MS Tested

View Report

FOR RESEARCH PURPOSES ONLY. This product is strictly for laboratory and research use. Not for human consumption, medical treatment, or any clinical application. By ordering, you confirm you are a qualified researcher or represent a legitimate research institution.

CJC-1295 + Ipamorelin Blend: Key Facts

CJC-1295 + Ipamorelin Blend is a growth factors research peptide supplied by LyzeLabs as a lyophilized reference standard, strictly for laboratory research use. It is available in 1 format starting at $355 per kit. Each batch is independently HPLC-verified at 99.24% purity by Janoshik Analytical, with the certificate of analysis published on the lab-results page and matched to the lot number printed on the vial.

Third-party verified batch

Compound	CJC-1295 + Ipamorelin Blend
Research category	Growth Factors
Available formats	10mg*10vials
Starting price	From $355 USD per kit
Purity	99.24% verified (third-party HPLC, Janoshik)
Test method	HPLC / ESI-MS
Certificate of analysis	Published online, matched to the vial lot number
Intended use	Laboratory research use only. Not for human consumption.
Handling	Supplied lyophilized, store per the stability guide

What Researchers Say

Dr. Meera Krishnan

Netherlands

"Our neuroendocrinology lab at a pharmaceutical research facility has been using LyzeLabs CJC-1295 + Ipamorelin Blend for synergistic GH secretion research for 9 months. The dual-pathway amplification is exceptional - our primary rat pituitary cell assays consistently show 11-14x GH release (ELISA quantification) compared to 4.5x for CJC-1295 alone or 5.8x for Ipamorelin alone, confirming true synergistic supraadditivity from cAMP-PKA and calcium pathway convergence. We independently verified >98% purity for both components via HPLC (two distinct peaks with proper retention times) and mass spec confirmed molecular weights (CJC-1295: 3367.3 Da, Ipamorelin: 711.4 Da). The pre-formulated blend eliminates mixing variability we encountered when administering separate peptides - batch-to-batch GH secretion reproducibility improved dramatically (CV <8% across 12 experiments vs >18% with manual mixing). We measured dual receptor activation: cAMP accumulation assays show robust GHRH-R Gs signaling, calcium imaging demonstrates GHS-R1a Gq activation with IP3-mediated calcium release, and the convergence produces supraadditive GH vesicle exocytosis. Mechanistically, we used PKA inhibitors (H-89) and calcium chelators (BAPTA-AM) confirming synergy requires both pathways intact - blocking either reduces GH to single-pathway levels. The selectivity of Ipamorelin is valuable - no appetite stimulation (unlike GHRP-6), minimal cortisol elevation (unlike GHRP-2), enabling clean GH studies without confounding metabolic effects. Delivery to Berlin takes 10-12 days with proper cold-chain packaging. The CP10 specification is perfect for our multi-week dual-pathway protocols. This is the gold standard combination secretagogue formulation for GH research internationally."

2025-11-13

Klara S.

United States

"Smooth from order to door. Answered on WhatsApp within the hour."

2025-11-10

D. Whitman

Sweden

"Held up in testing. Reordering without a second thought."

2025-11-07

About This Product

CJC-1295 + Ipamorelin Blend Research Guide

One Vial, Two Receptors, One Coordinated GH Pulse

The CJC-1295 + Ipamorelin blend is the premixed version of what is arguably the most studied growth hormone secretagogue stack in the research peptide literature. The two compounds are combined in a ratio matched to published protocols so that researchers can run coordinated GHRH plus ghrelin receptor activation in a single reconstitution rather than mixing two separate vials.

Why the Stack Beats Either Peptide Alone

CJC-1295 activates the GHRH receptor on somatotroph cells in the anterior pituitary. Ipamorelin activates the separate ghrelin receptor (GHSR) on the same cells. The two receptor pathways converge on growth hormone release but do so through different intracellular signaling cascades (cAMP for GHRH, IP3/calcium for ghrelin). When both receptors fire simultaneously, the downstream GH release is larger than the additive expectation of either peptide alone. That synergy is the mechanistic reason the stack exists.

Advantages of the Blend Format

Dose consistency: a single reconstitution eliminates the inter-vial variance introduced by mixing two separate preparations
Protocol simplicity: one injection event instead of two, which matters for multi-subject research logistics
Matched ratios: the premixed ratio aligns with published research stacks, reducing setup time for replicated protocols
Cost efficiency: typically priced below the combined cost of buying two separate vials at equivalent total peptide mass

Research Applications

Pulsatile GH dynamics research where the blend produces a coordinated sharp pulse
Dual-receptor mechanism studies comparing single versus combined activation
Age-related GH decline research requiring physiologic pulse restoration
Comparative work against direct exogenous HGH to probe endogenous versus exogenous GH effects
Long-duration anabolic research protocols

Quality Standards

Purity: 99 percent plus verified independently for each peptide component (Janoshik Analytical)
Blend Ratio: documented on the per-batch Certificate of Analysis
Form: lyophilized powder, premixed in sterile vials
Storage: refrigerator for near-term use, minus 20 degrees Celsius long-term
Documentation: batch-matched Certificate of Analysis for both components published at /lab-results

For the full mechanism story and the DAC versus no-DAC choice for the CJC-1295 component, see the [CJC-1295 + Ipamorelin stack guide](/blog/cjc-1295-ipamorelin-stack-guide).

For research purposes only. Not for human consumption or therapeutic use.

Research Context for CJC-1295 + Ipamorelin Blend

Growth Factor Research Context

Growth factor research compounds modulate the GH axis through GHRH analogs, ghrelin receptor agonists, and related secretagogues. Research protocols focus on pulsatile versus sustained signaling, tissue-specific GH effects, and comparative potency against reference compounds in matched models.

CJC-1295 + Ipamorelin Blend ships as a lyophilized research reagent through the LyzeLabs™ catalog in the Growth Factors category, available as a single research-grade format. Every batch is independently verified by Janoshik Analytical, with the full HPLC chromatogram and mass spectrometry confirmation published on the LyzeLabs lab results page and matched to the lot number printed on your vial.

Related Research Guides

CJC-1295 and Ipamorelin Stack Guide

Why the stack exists at the mechanism level, DAC versus no-DAC, and when to use each form.

How to Read a Peptide Certificate of Analysis

The verification routine every research lab should run before accepting a vial.

How to Reconstitute a Research Peptide

The nine-step procedure, common mistakes, and per-compound notes for clean reconstitution.

Other Compounds in the Growth Factors Category

Research Tools for This Compound

Frequently Asked Questions

CJC-1295 + Ipamorelin Blend

$355